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Abstract Immune responses are tightly regulated via
signaling through numerous co-stimulatory and co-inhibi-
tory molecules. Exploitation of these immune checkpoint
pathways is one of the mechanisms by which tumors evade
and/or escape the immune system. A growing under-
standing of the biology of immune checkpoints and tumor
immunology has led to the development of monoclonal
antibodies designed to target co-stimulatory and co-inhib-
itory molecules in order to re-engage the immune system
and restore antitumor immune responses. Anti-cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) antibodies
were among the first to be tested in the clinic, and ipi-
limumab was the first immune checkpoint inhibitor
approved for an anticancer indication. Agents targeting the
programmed death 1 (PD-1) pathway, either PD-1 or one of
its ligands, programmed death ligand 1, are in active
clinical development for numerous cancers, including
advanced melanoma and lung cancer. Understanding the
different mechanisms of action, safety profiles, and
response patterns associated with inhibition of the CTLA-4
and PD-1 pathways may improve patient management as
these therapies are moved in to the clinical practice setting
and may also provide a rationale for combination therapy
with different inhibitors. Additional immune checkpoint
molecules with therapeutic potential, including lymphocyte
activation gene-3 and glucocorticoid-induced tumor
necrosis factor receptor-related gene, also have inhibitors
in early stages of clinical development. Clinical responses
and safety data reported to date on immune checkpoint
inhibitors suggest these agents may have the potential to
markedly improve outcomes for patients with cancer.
Key Points
Immune checkpoint inhibitors are designed to
interrupt inhibitory immune signals and restore
immune responses against tumors.
Numerous immune checkpoint inhibitors are in
advanced stages of development and show activity
across multiple tumor types, including advanced
melanoma and advanced non-small-cell lung cancer.
Understanding the mechanism-associated adverse
events and response patterns is important to the
management of patients as these drugs are moved
into the clinical practice setting.
1 Introduction
Rudolph Virchow may have been one of the first physi-
cians in modern times to observe the link between the
immune system and malignancy in what he termed ‘‘lym-
phoreticular infiltrates’’. These infiltrates were leukocytes
surrounding malignant tumors, and he hypothesized that
proinflammatory states might induce normal tissues to
become malignant [1]. Since then, we have learned a great
deal about how the immune system responds and reacts to
tumors, which tumor-specific antigens are recognized as
foreign, and how immune responses can be manipulated
and harnessed to enhance tumor cell killing.
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Recently, it has been recognized that, on its own, tumor
peptide presentation by major histocompatibility complex
(MHC) to T-cell receptors is inadequate for successful
T-cell activation and immune destruction of cancer cells.
Co-regulatory signals, either inhibitory or stimulatory, are
also required [2, 3]. T cells play a critical role in cell-
mediated tumor immunity, and do so through an intricate
counterbalance of co-stimulatory and co-inhibitory cell-to-
cell signals between various components of the immune
system. This system of checks and balances is necessary
not only to allow a powerful destructive response against
both pathogens and malignancies, but also to prevent
immune responses from being generated against normal
tissues. Critical ‘checkpoints’ control and fine-tune the
immune system through regulation of this complex net-
work of co-stimulatory and co-inhibitory signaling [3]. In
this paper, we review some of the important immune
checkpoint molecules elucidated to date, as well as efforts
to block these molecules in order to shift the balance
towards antitumor immunity. We also describe some of the
complexities and challenges encountered using these
checkpoint inhibitors in the clinic.
2 Cytotoxic T-Lymphocyte-Associated Antigen
(CTLA)-4
2.1 Background
More than 40 years of research has led to the development
of a two-signal theory of T-cell activation: antigenic
stimulation of the T-cell receptor (TCR) (signal 1) together
with co-stimulation by other molecules on the cell surface
(signal 2) [2, 3]. One of the key co-stimulatory mechanisms
involves the interaction of CD28 on the surface of the T
cell with B7 molecules CD80 or CD86 on antigen-pre-
senting cells. CTLA-4, a transmembrane glycoprotein with
considerable homology to CD28, binds to the same B7
ligands, as such (Fig. 1). Upon TCR stimulation by anti-
gens, T cells express CTLA-4, which can bind B7 mole-
cules; however, unlike CD28, CTLA-4 inhibits T-cell
responses and is important for maintenance of immune
tolerance. Expression of CTLA-4 raises the activation
threshold and attenuates clonal expansion; thus, a produc-
tive T-cell response ensues only upon a net co-stimulatory
signal.
2.2 Efficacy of CTLA-4 Inhibitors
2.2.1 Ipilimumab
Ipilimumab, one of the best-studied monoclonal antibodies
targeting CTLA-4 (Table 1 [4–16]), has been evaluated in
a clinical trial program of more than 2,000 patients with a
variety of solid tumors [4, 5, 17–19]. Ipilimumab (Yer-
voy), administered every 3 weeks for four doses, gained
US FDA approval in 2011 for the treatment of unresectable
or metastatic melanoma, based on data from two phase III
randomized trials showing improvement on median overall
survival (OS) over control arms in patients with melanoma
[4, 5, 20]. One of the pivotal phase III trials evaluated
ipilimumab with or without gp100 vaccine in previously
treated patients with advanced melanoma. Although the
best overall response rates were modest, 10.9 % in the i-
pilimumab-alone group and 5.7 % in the ipilimumab plus
gp100 vaccine group, some patients in both groups main-
tained an objective response for at least 2 years [4]. In this
trial, the 3-year OS rate for ipilimumab monotherapy was
20 % [4], which compares favorably with the 3-year OS
rate of 17 % for historical control patients receiving stan-
dard of care chemotherapy in a separate clinical trial [21]
(Table 2 [4, 5, 7, 18, 19, 21–33]). The other pivotal phase
III trial was conducted in treatment-naı¨ve patients with
metastatic melanoma and compared ipilimumab plus
dacarbazine versus dacarbazine plus placebo [5]. Although
the dose and schedule were slightly different, the rate of
best overall response was 15 % in the ipilimumab plus
dacarbazine group versus 10 % for the dacarbazine plus
Antigen presenting cell/Tumor T cell
MHC class I or II TCR Signal 1
InhibitionLAG-3
CD80 or CD86 CD28 Signal 2 – activation
CD80 or CD86 CTLA-4 Inhibition
PD-L1 or PD-L2 PD-1 Inhibition
GAL9 TIM3 Inhibition
GITRL GITR Activation
Fig. 1 T-cell activation and immune checkpoint pathways. T-cell
activation requires two signals: (1) presentation of antigenic peptides
by MHC to the TCR and (2) co-stimulation, typically via CD28:CD80
or CD28:CD86 ligation. Immune checkpoint pathways comprising
receptors on T cells and ligands on antigen-presenting cells and/or
tumors fine-tune immune responses via T-cell activation or inhibition.
CTLA-4 cytotoxic T-lymphocyte-associated antigen 4, GAL9 galec-
tin-9, GITR glucocorticoid-induced TNF receptor-related gene, GIT-
RL glucocorticoid-induced TNF receptor-related gene ligand, LAG-3
lymphocyte activation gene-3, MHC major histocompatibility com-
plex, PD-1 programmed death-1, PD-L1 programmed death ligand 1,
PD-L2 programmed death ligand 2, TCR T-cell receptor, TIM3 T-cell
immunoglobulin and mucin domain 3, TNF tumor necrosis factor
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Table 1 Immune checkpoint inhibitors in clinical development [4–16]
Name Company Description of agent
Ipilimumab [4, 5] Bristol-Myers Squibb Human IgG1 mAb against CTLA-4
Tremelimumab [6] MedImmune/AstraZeneca Human IgG2 mAb against CTLA-4
Pembrolizumab (MK-3475) [7] Merck Humanized IgG4 mAb against PD-1
Nivolumab (BMS-936558) [8] Bristol-Myers Squibb Human IgG4 mAb against PD-1
Pidilizumab (CT-011) [9] CureTech Humanized IgG1 mAb against PD-1
AMP-224 [10] Amplimmune; GlaxoSmithKline PD-L2-IgG recombinant fusion protein
MPDL3280A [11, 12] Genentech/Roche Human IgG mAb against PD-L1
BMS-936559 [13] Bristol-Myers Squibb Human IgG4 mAb against PD-L1
MEDI4736 [14] MedImmune/AstraZeneca Human mAb against PD-L1
IMP321 [15] Immutep Soluble LAG-3 Ig fusion protein and MHC class II agonist
TRX518 [16] GITR, Inc Humanized mAb against GITR
CTLA-4 cytotoxic T-lymphocyte-associated antigen 4, GITR glucocorticoid-induced tumor necrosis factor receptor-related gene, IgG immu-
noglobulin G, LAG-3 lymphocyte activation gene-3, mAb monoclonal antibody, MHC major histocompatibility complex, PD-1 programmed
death 1, PD-L1 programmed death ligand 1, PD-L2 programmed death ligand 2
Table 2 Preliminary efficacy data with immune checkpoint inhibitors or controls from individual (not head-to-head) trialsa [4, 5, 7, 17, 18,
21–33]
Advanced tumor setting Agent or control Median PFS Median OS Survival rate Reference(s)
Melanoma CTX (CTX-naı¨ve pts) ND 9.1–10.7 months 1-year: 36 %
3-year: 12–17 %
[5, 21]
Ipilimumab 2.9 months 10.1 months 3-year: &20 % [4]
Tremelimumab ND 12.6 months 3-year: 21 % [21]
Pembrolizumab 5.5 months NR 1-year: 69 % [7]
Nivolumab 3.7 months 17.3 months 1-year: 63 %
3-year: 41 %
[22]
Pidilizumab 1.9 months ND 1-year: 65 % [23]
Nivolumab plus ipilimumab 27 weeks 40 months 1-year: 85 %
2-year: 79 %
[24]
NSCLC CTX (CTX-naı¨ve pts) 4.2 months 8.3 months 1-year: 39 %
2-year: 18 %
[18]
Pembrolizumab 10–27 weeksb 51 weeks ND [25–27]
Nivolumab (previously-treated pts) 2.3 months 9.9 months 1-year: 42 %
3-year: 24 %
[28]
Nivolumab (CTX-naı¨ve pts) 36.1 weeks NR 1-year: 75 % [29]
RCC Sorafenib 3.6–5.7 months 11.0–19.2 months 3-year: &25 % [30–32]
Nivolumab 2.7–4.2c months 18.2–24.7c months 2.5-year: &35 % [33]
CRPC Placebo 3.1 months 10.0 months 1-year: 40 %
2-year: 15 %
[17]
Ipilimumab 4.0 months 11.2 months 1-year: 47 %
2-year: 26 %
[17]
CRPC castration-resistant prostate cancer, CTX chemotherapy, ND no data, NR not reached, NSCLC non-small-cell lung cancer, OS overall
survival, PFS progression-free survival, pts patients, RCC renal cell carcinoma
a Important: data are not from head-to-head trials, and the trials differ by patient characteristics, patient numbers, and length of follow-up,
therefore direct comparisons across trials and agents have limited validity; trials in tumor types with PFS and OS data were included
b Based on differing studies and data-cuts
c Dose-dependent
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placebo group, while the median duration of response was
19.3 versus 8.1 months for the dacarbazine plus placebo
group. Responses lasting at least 2 years were observed in
both treatment groups. The 3-year survival rate with ipi-
limumab plus dacarbazine was significantly higher than
dacarbazine plus placebo: 20.8 versus 12.2 % (P \ 0.001).
Ipilimumab was evaluated as adjuvant therapy following
complete resection of stage III melanoma in a phase III
trial in patients at high risk of recurrence [34]. Patients
receiving ipilimumab had a significantly increased median
OS as compared with patients receiving placebo: 26.1
versus 17.1 months (P = 0.0013). The 3-year rates of
recurrence-free survival were 47 % for ipilimumab and
35 % for placebo.
Preclinical studies suggest that chemotherapy can
induce the release of tumor-specific antigens, thereby ini-
tiating T-cell activation and sensitizing tumor cells to
T-cell-mediated killing [35]. These observations provided
the rationale for combining immunotherapy with cytotoxic
agents to improve responses in patients with melanoma,
and also led to the initiation of clinical trials evaluating
ipilimumab with chemotherapy in lung cancer. A phase II,
randomized study provided evidence that sequential ipi-
limumab is more effective than concurrent ipilimumab
when administered with paclitaxel/carboplatin in chemo-
therapy-naı¨ve stage IIIB/IV patients with non-small-cell
lung cancer (NSCLC). The median OS with sequential i-
pilimumab, concurrent ipilimumab, and the control regi-
men was 12.2, 9.7, and 8.3 months, respectively. In this
trial, patients with squamous histology exhibited better
outcomes (median immune-related progression-free sur-
vival [irPFS] and OS) with sequential ipilimumab dosing
than did patients with non-squamous histology [18]. Based
on these findings, a phase III trial evaluating OS in patients
with squamous NSCLC receiving sequential ipilimumab
after chemotherapy was initiated (Table 3 [16]).
Ipilimumab is also being investigated in the setting of
metastatic castration-resistant prostate cancer (mCRPC). In a
phase III trial of ipilimumab versus placebo in post-docetaxel
patients with mCRPC receiving a single dose of radiother-
apy, the primary endpoint of OS was not reached; however,
pre-specified subset analyses suggested that ipilimumab may
be more active in patients with favorable prognostic factors,
including no visceral disease, alkaline phosphatase \1.5
upper limit of normal, and hemoglobin C11 g/dL [17].
Results from this study support the investigation of ipi-
limumab in the ongoing phase III, CA184-095 study among
chemotherapy-naı¨ve patients with mCRPC (Table 3 [16]).
2.2.2 Tremelimumab
Tremelimumab is a fully human immunoglobulin G (IgG)-
2 monoclonal antibody targeting CTLA-4 [6] (Table 1 [4–
16]). Tremelimumab provided durable responses in 6.6 %
of patients in a phase II trial of patients with advanced
melanoma, as compared with the objective response rates
(ORRs) of 5.7 and 10.9 % seen in the phase III trial of
ipilimumab with or without vaccine [4, 6]. However, the
phase III trial of tremelimumab monotherapy failed to
demonstrate a statistically significant survival advantage
over chemotherapy in first-line treatment of patients with
metastatic melanoma [21]. Patient selection criteria, dosing
regimen, and use of ipilimumab as salvage therapy for
patients in the control arm were potential reasons for the
lack of survival benefit.
Tremelimumab showed evidence of activity against
previously treated malignant mesothelioma in a small
(N = 29) phase II single-arm trial [36]. Four patients had
partial responses, and 11 patients had stable disease of
median duration 7.7 months (range 2.6–16.6?), with a
median OS of 11.3 months. Based on these results, a phase
II trial of tremelimumab in malignant mesothelioma has
been initiated (Table 3 [16]).
2.3 Safety of CTLA-4 Inhibitors
The cumulative safety data across many trials show that
agents that inhibit CTLA-4 are generally safe, with unique,
but usually manageable, side effects that are linked to their
mechanism of stimulating immune responses. Multiple
phase II and III trials have characterized these immune-
related adverse events (irAEs) of CTLA-4 inhibition.
Overall, irAEs were observed in 58–63 % of patients
treated with ipilimumab, with 5–26 % of patients experi-
encing grade 3/4 irAEs [4, 17, 37] (Table 4 [4, 7, 8, 12–14,
17, 21, 23, 26, 28, 36, 38–40]). In the phase III trial
investigating ipilimumab treatment with or without vac-
cine, skin-related irAEs (including pruritus, rash, and ery-
thema) and gastrointestinal irAEs (including diarrhea and
colitis) were the most common, occurring in 29–44 % of
patients; endocrine disorders were reported in 4–8 % of
patients [4]. Some of the more rare adverse events (AEs)
(B1 % for each) reported during treatment with ipi-
limumab include uveitis, conjunctivitis, and neuropathy
[37]. Interestingly, when ipilimumab was given with
dacarbazine, immune-mediated grade 3/4 hepatitis occur-
red in 32 % of patients, while the rates of gastrointestinal
events, such as colitis, were lower than expected based on
previous trials [5]. As adjuvant therapy, ipilimumab had a
safety profile generally consistent with that seen in patients
with advanced melanoma, although the incidence of some
irAEs (e.g. endocrinopathies) was higher. Also, five
patients (1 %) in the ipilimumab arm died due to treatment-
related AEs versus 0 patients in the placebo group [34].
Tremelimumab has a similar irAE profile to ipilimumab.
The most common irAEs with tremelimumab were













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2000 K. Shih et al.
gastrointestinal (18 % grade 3–5), dermatologic (rash 33 %
all grades, 2 % grade 3–5), and endocrine (thyroid/pan-
hypopituitarism/adrenal insufficiency 7 %) in nature [21]
(Table 4 [4, 7, 8, 12–14, 17, 21, 23, 26, 28, 36, 38–40]).
irAEs for CTLA-4 inhibitors tend to occur during the
induction period or first 12 weeks of therapy, but, in rare
cases, can occur in the weeks and even months following
discontinuation of therapy [37]. Grade 2 irAEs are usually
responsive to interruption of therapy and institution of low-
dose steroids (0.5 mg/kg/day of prednisone), and grade 3
and higher irAEs are generally responsive to high-dose
steroids (1–2 mg/kg/day of prednisone or equivalent),
although the steroid-refractory patients (reported as 2–8 %
of patients) [20, 41] may require the use of alternate
immunosuppressive agents, such as infliximab (5 mg/kg)
once every 2 weeks until symptom resolution, followed by
a prolonged steroid taper [42]. Prompt recognition, man-
agement, and monitoring of grade 2 and higher irAEs are
critical for the successful resolution of these toxicities,
although such events can often take weeks to months to
return to baseline. Algorithms for the management of irAEs
with ipilimumab have been published by Fecher et al. [37].
Unfortunately, prophylactic steroids and other preventive
strategies to avoid irAEs have not shown clinical benefit to
date [37]. An interesting and consistent observation is that
a higher incidence of irAEs, particularly grade 3/4 irAEs,
has been associated with a higher proportion of patients
eventually achieving an objective response [43]. However,
as grade 3/4 irAEs can be life threatening, it is recom-
mended that patients experiencing severe irAEs discon-
tinue ipilimumab [20, 37].
3 Programmed Death-1 (PD-1) and Programmed
Death Ligand 1 (PD-L1)
3.1 Background
PD-1 (CD279) is also a co-inhibitory molecule that plays
an important role in the balance of tumor immunity and
inflammatory reactions [3, 44]. However, in contrast to
CTLA-4, PD-1 appears to play a greater role in limiting
and modulating the activity of T cells in peripheral tissues
and organs during inflammatory responses in an effort to
prevent host tissue damage. PD-1 expression is induced on
activated T cells, and the interaction between PD-1 and one
of its ligands—typically PD-L1 (B7-H1, CD274) or PD-L2
(B7-DC, CD273)—on the surface of tumors leads to a
diminished antitumor response and has been associated
with a poorer patient outcome [44]. High levels of PD-1
expression on antigen-experienced CD8? T cells are
associated with the loss of effector functions, including the
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2, tumor necrosis factor (TNF)-a, and interferon (IFN)-c—
a process termed T-cell ‘exhaustion’ or ‘tolerance’. In this
state, tumor-infiltrating lymphocytes become tolerant and
are less capable of carrying out antitumor immune
responses as a result of chronic antigen exposure and
prolonged negative immune regulation. While both CTLA-
4 and PD-1 are immune checkpoint inhibitors, CTLA-4 is
thought to act earlier in the process of T-cell activation,
whereas PD-1 plays a role in attenuating T-cell responses
later in the process, after T cells have migrated to the tumor
microenvironment [44] (Fig. 2).
Given these observations, both PD-1 and PD-L1 anti-
body blockade may be a promising target for cancer
immunotherapy (Fig. 2) [3, 45]. Anti-PD-1 antibodies are
designed to inhibit PD-1 from engaging with any of its
ligands, thereby preventing both PD-1:PD-L1 and PD-
1:PD-L2 binding. In contrast, anti-PD-L1 agents prevent
PD-1:PD-L1 binding, but not necessarily PD-1:PD-L2
binding. There is evidence that PD-L1 may bind CD80
(B7-1) on T cells, leading to a down-regulatory signal;
hence, anti-PD-L1 could inhibit this interaction as well [3,
44]. Given the current understanding that PD-1:PD-L1
interactions are a predominant mechanism of tumor
immune evasion, whether agents targeting PD-1 versus
PD-L1 will have different clinical profiles is unknown.
To date, all data reported for PD-1 pathway inhibitors
have been in phase I or II studies without control arms. The
ongoing phase II and III trials that include control arms
should provide data with greater context. Table 2 lists PFS
and OS data from historical controls and studies where
these data were available. However, as the studies differ
greatly in terms of patient characteristics, study sizes, and
length of follow-up, direct comparisons should be made
with great caution.
3.2 Efficacy with PD-1 Inhibitors
3.2.1 Pembrolizumab (MK-3475)
Pembrolizumab (MK-3475) is a humanized IgG4 mono-
clonal antibody against PD-1 [7] (Table 1 [4–16]). A phase
I study, including expansion cohorts, evaluated pem-
brolizumab treatment in patients with advanced melanoma
who had previously received or not received ipilimumab
[7]. The overall response rate across all doses was 34 %;
88 % of responses were ongoing at the time of analysis and
the median duration of response had not been reached.
Prior treatment with immunotherapy, including ipilimumab
and IL-2, did not preclude activity of pembrolizumab, nor
were higher rates of AEs observed in patients who had
received previous immunotherapy compared with those
who had not. Preliminary survival data of pembrolizumab
and other PD-1 pathway agents is listed in Table 2 [4, 5, 7,
18, 19, 21–33].
Pembrolizumab was also investigated in a phase I study
in patients with previously treated NSCLC [25, 26].
Interim data analysis revealed that, in a cohort of 217
patients with NSCLC, the ORR was 18 % based on
immune-related response criteria (irRC), and the median
OS was 51 weeks. irRC have been used primarily to assess
responses in patients with melanoma, and have not been
validated in other cancers [46]. Responses were seen in
patients with non-squamous and squamous histology, and
in current/former and never smokers. [25, 26]. As a first-
line therapy for NSCLC, pembrolizumab reported pre-
liminary ORRs of 47 % by irRC. Median PFS was
27 weeks (Response Evaluation Criteria in Solid Tumors





























Fig. 2 Inhibiting the CTLA-4 and PD-1 immune checkpoint path-
ways to restore antitumor immune responses. In peripheral lymphoid
organs and tissues, anti-CTLA-4 antibodies block CTLA-4 from
binding CD80/86 on APCs and prevent T-cell inhibition. In the tumor
microenvironment, PD-L1 and/or PD-L2 expression inhibits PD-1-
expressing T cells. Interruption of PD-1:PD-L1 and PD-1:PD-L2
binding by anti-PD-1 antibodies or interruption of PD-1:PD-L1
binding by anti-PD-L1 antibodies restores T-cell immune responses.
APC antigen-presenting cell, CTLA-4 cytotoxic T-lymphocyte-asso-
ciated antigen 4, MHC major histocompatibility complex, PD-1
programmed death-1, PD-L1 programmed death ligand 1, PD-L2
programmed death ligand 2, TCR T-cell receptor
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Pembrolizumab also showed antitumor activity in
patients with head and neck cancer in a phase I study [47].
Responses were seen in 20 % (11/56) of evaluable patients,
which included human papillomavirus-positive and -nega-
tive tumors (Table 3 [16]).
3.2.2 Nivolumab
Nivolumab (BMS-936558) is a fully human IgG4 PD-1
immune checkpoint inhibitor [8] (Table 1 [4–16]). A phase
I, dose-escalating study in multiple tumor types reported
objective responses with nivolumab in a substantial portion
of patients with melanoma, NSCLC, or renal cell carci-
noma (RCC), but no objective responses in patients with
colorectal cancer (CRC) or CRPC [8]. In patients with
melanoma treated with nivolumab across all doses in the
phase I trial, the ORR was 32 % and the median duration
of response was 99 weeks. The median OS was
17.3 months and 1-, 2-, and 3-year survival rates were 63,
48, and 41 %, respectively [22] (Table 2 [4, 5, 7, 18, 19,
21–33]).
In the phase I trial among patients with NSCLC and
across all doses, the ORR was 17 % (22/129), the estimated
median response duration was 74 weeks, and overall 1- and
2-year survival rates were 42 and 24 %, respectively [28].
Ongoing trials are evaluating nivolumab alone or in com-
bination with chemotherapy, erlotinib, or ipilimumab in
patients with chemotherapy-naı¨ve NSCLC, and have
reported initial evidence of antitumor activity [29, 48–50].
With first-line nivolumab monotherapy in a phase I trial,
the initial ORR was 30 %, median PFS was 36.1 weeks,
and median OS was not reached (range 13.3–89.1?) in 20
evaluable patients. The 1-year OS rate was 75 % [29].
In phase II study in patients with previously-treated
RCC, the overall response rate was 21 % (35/168), with the
majority of responses lasting [1 year [33]. Across the
evaluated doses, the PFS ranged from 2.7 to 4.2 months,
and the median OS ranged from 18.2 to 24.7 months. The
survival rate was approximately 35 % at 2.5 years [33]
(Table 2 [4, 5, 7, 18, 19, 21–33]). Phase II and III trials of
nivolumab are ongoing in melanoma, NSCLC, RCC, and
squamous head and neck cancer (Table 3 [16]).
3.2.3 Pidilizumab (CT-011)
Pidilizumab (CT-011) is a humanized anti-PD-1 IgG1
monoclonal antibody [9] (Table 1 [4–16]). Pidilizumab
was evaluated in patients with stage IV melanoma in a
phase II open-label study. The ORR using irRC was 6 %,
the median PFS was 1.9 months, and the 1-year survival
rate was 65 % [23] (Table 2 [4, 5, 7, 18, 19, 21–33]).
Pidilizumab has also shown evidence of efficacy in
patients with hematologic malignancies [51]. Separately,
pidilizumab after autologous hematopoietic stem-cell
transplantation (AHSCT) was evaluated in a phase II trial
in patients with diffuse large B-cell lymphoma (DLBCL)
or primary mediastinal large B-cell lymphoma [9]. A total
of 66 patients completed all treatment cycles, and PFS at
16 months from the start of treatment was 72 %. This
compares favorably with the PFS rate at 18 months of
52 % in a historical group of patients with DLBCL with
similar characteristics (i.e., would have met the eligibility
criteria for the study, including no progression or relapse
within 2 months of AHSCT) who had received high-dose
chemotherapy followed by AHSCT [9, 52]. Among the 35
patients with measurable disease after transplant, the
overall response rate with pidilizumab treatment was 51 %,
and the complete remission rate was 34 % [9].
3.2.4 AMP-224
AMP-224 is a recombinant fusion protein comprising the
extracellular domain of PD-L2 and the Fc region of human
IgG [10] (Table 1 [4–16]). This agent is designed to bind
PD-1, and preclinical studies suggest its mechanism of
action may differ from monoclonal antibody blockade. A
phase I trial evaluating the safety of AMP-224 in patients
with advanced cancer is ongoing (NCT01352884) [53].
Infusion reactions were common, occurring in 69 % of
patients across dose cohorts. It is unclear whether this study
is moving forward, as a high rate of infusion reactions and
lack of efficacy have been observed compared with other
PD-1 inhibitors.
3.3 Safety of PD-1 Inhibitors
While no head-to-head trials have been conducted, the
safety profiles of the anti-PD-1 agents seem to be generally
similar. In the largest and most mature studies of pem-
brolizumab and nivolumab, grade 3/4 treatment-related
AEs were reported in 10–22 % of patients [7, 8, 26, 38].
The most common treatment-related AE was fatigue in all
studies (20–36 % all grades, 2 % grade 3/4). Potential
immune-related select AEs were also commonly reported:
dermatologic toxicities (pruritus B24 % all grades, \1 %
grade 3/4; rash 6–20 % all grades,\1 % grade 3/4; vitiligo
B11 % all grades, 0 % grade 3/4), gastrointestinal toxici-
ties (diarrhea 7–16 % all grades, B1 % grade 3/4; nausea
6–12 % all grades,\1 % grade 3/4), and endocrinopathies
(hypothyroidism 2–8 % all grades, \1 % grade 3/4;
hyperthyroidism 1–2 % all grades, \1 % grade 3/4).
Arthralgia (all grades) was reported in 4–16 % of patients,
and grade 3/4 in \1 %. Pneumonitis of all grades was
noted in 3 % of pembrolizumab- or nivolumab-treated
patients, with B1 % of patients developing grade 3/4
pneumonitis. Although rare, three deaths due to
2006 K. Shih et al.
pneumonitis in nivolumab-treated patients are concerning.
Nivolumab or pembrolizumab in patients who had received
prior ipilimumab showed similar safety profiles to those of
ipilimumab-naı¨ve patients, supporting the sequential use of
these therapies [54, 55].
3.4 Efficacy with PD-L1 Inhibitors
3.4.1 MPDL3280A
MPDL3280A is a human anti-PD-L1 monoclonal antibody
[11, 12] (Table 1 [4–16]). MPDL3280A is being assessed
in a dose-ranging phase I study in patients with multiple
tumor types. Interim results from 53 evaluable patients
with NSCLC revealed an ORR of 23 % in patients across
squamous and non-squamous histologies, including several
patients with rapid tumor shrinkage [39]. Some patients
(not included in the ORR) had delayed responses after
apparent radiographic progression. Most responses were
ongoing at the time of analysis. The ORR in patients with
RCC was 13 %; durable responses were seen in patients
with clear cell and non-clear cell disease [11]. In patients
with urothelial bladder cancer, the ORR was 25 % (17/67)
[12]. Phase II and III trials evaluating MPDL3280A in
advanced lung cancer, advanced RCC, and urothelial
bladder cancer are ongoing (Table 3 [16]).
3.4.2 BMS-936559
BMS-936559 is a fully human IgG4 monoclonal antibody
directed against PD-L1 [13] (Table 1 [4–16]). The safety
and activity of BMS-936559 was assessed in a phase I
dose-escalating study in patients with advanced solid
tumors [13]. Clinical activity was observed in patients with
melanoma, NSCLC, RCC, CRC, ovarian, or pancreatic
cancer, but not for patients with gastric or breast cancer.
ORRs for patients with melanoma, NSCLC, RCC, and
ovarian cancer were 17, 10, 12, and 6 %, respectively, and
responses lasted for C1 year in 8 of 16 patients with at
least 1 year of follow-up. No additional trials of BMS-
936559 are currently listed in ClinicalTrials.gov [16].
3.4.3 MEDI4736
MEDI4736 is a human IgG1 monoclonal antibody that
binds PD-L1 [14] (Table 1 [4–16]). MEDI4736 is being
investigated in multiple tumor types, including melanoma,
NSCLC, squamous head and neck cancer, and pancreatic
cancer in a phase I trial. A preliminary analysis reported
ORRs of 13 % (6/47) in patients with NSCLC and 14 % (3/
22) in patients with squamous head and neck cancer, and
evidence of activity against pancreatic and gastroesopha-
geal cancer [14]. Numerous studies of MEDI4736 are
planned or ongoing in patients with NSCLC or other
malignancies (Table 3 [16]).
3.5 Safety of PD-L1 Inhibitors
The types of AEs reported with PD-L1 agents seem similar
to those targeting PD-1, but the incidence of AEs appears
to be lower. The reported rate of grade 3/4 treatment-
related AEs across studies and tumor types ranged from 4
to 13 % [11–14, 39]. Fatigue (12–20 % all grades, 0–2 %
grade 3/4), gastrointestinal AEs (diarrhea 5–9 % all grades,
0 % grade 3/4; nausea 6–14 % all grades, 0–1 % grade
3/4), dermatologic AEs (rash 7–9 % all grades,\1 % grade
3/4; pruritus 6 % all grades, \1 % grade 3/4), and endo-
crinopathies (hypothyroidism 2–3 % all grades, \1 %
grade 3/4) were the most common.
BMS-936559 had a higher reported rate of infusion-
related reactions (10 % all grades, B1 % grade 3/4) and
arthralgia (7 % all grades, 0 % grade 3/4) than other PD-
L1-targeting agents [13] (Table 4 [4, 7, 8, 12–14, 17, 21,
23, 26, 28, 36, 38–40]).
3.6 PD-L1 as a Predictive Biomarker
Emerging evidence suggests that PD-L1 expression on pre-
treatment tumor specimens may be a predictive biomarker
of efficacy with PD-1 pathway inhibitors. Across agents,
studies, and tumor types, antitumor activity was generally
higher against PD-L1-positive tumors versus tumors with
low or negative staining for PD-L1 (Table 5 [11, 12, 14,
22, 28, 29, 39, 56–59]). However, the methodology,
amount of staining (or ‘cut-off’) required to qualify as a
PD-L1-positive tumor and timing of sample collection
(archival or immediately pre-treatment) varied across
studies. Thus, while these preliminary findings are
encouraging, data on tumor PD-L1 expression as a poten-
tial predictive biomarker are evolving, and prospective
validation will be needed.
4 Immunotherapy Clinical Response Patterns
Across the various immunotherapy clinical development
programs, investigators have observed response patterns
that sometimes differ from the conventional responses
observed with cytotoxic agents. Standard response criteria
may not capture or adequately describe the responses
produced by novel immunotherapy; thus, clinical trials may
not always capture the full clinical benefit to patients who
receive immunotherapy. To better characterize this pattern
of response, new irRC were created that accounted for
antitumor response based on total measurable tumor bur-
den as measured by the sum of index lesions and new
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measurable lesions [46]. Time point response assessment
was also incorporated into the criteria, as two observations
at least 4 weeks apart were necessary to help distinguish
progression from ‘pseudoprogression’, in which there is an
initial increase in tumor size followed by tumor shrinkage.
The differences between World Health Organization
(WHO) criteria and the new irRC are listed in Table 6 [46].
It has also been determined that some of these new
response patterns to immune therapies are associated with a
favorable survival outcome and may include the following:
• Stable disease, which in some cases may be followed
by slow and steady decline of tumor burden. Durable,
stable disease lasting months or even years has been
observed in some patients.
• Reduction after an initial increase in tumor burden; this
observation has been associated with T-cell infiltration
into the tumor, giving the appearance of progressive
disease.
• Reduction in total tumor burden during or after the
appearance of new lesions, possibly due to the unique
mechanism of action of immunotherapy, as the acti-
vated immune system may take some time to mount an
effective antitumor response.
Time to response appears to be faster for agents that
block PD-1 or PD-L1 compared with the many weeks it
may take to observe tumor shrinkage in response to anti-
CTLA-4 treatment [8, 13, 21, 38, 46]. Additionally,
response rates in patients given anti-PD-1 or anti-PD-L1
treatment may be higher than in those receiving anti-
CTLA-4, although head-to-head trial data are not yet
available.
5 Other Immune Targets—Inhibitory and Stimulatory
In addition to CTLA-4 and PD-1, other classes of inhibi-
tory and stimulatory molecules have potential to be used as
anticancer immunotherapy. One inhibitory molecule that
has drawn much attention recently is lymphocyte activation
gene-3 (LAG-3), a CD4 homolog that binds to MHC class
II molecules (Fig. 1). LAG-3 is expressed on activated
CD4? and CD8? T cells, as well as B cells, natural killer
cells, and tumor-infiltrating lymphocytes, and is thought to
negatively regulate T-cell expansion by limiting T-cell
activation. However, LAG-3 knockout mice do not develop
overt autoimmunity, suggesting that it plays a more subtle
role in regulating T-cell function than the checkpoint
Table 5 PD-L1 expression and association with clinical activity [11, 12, 14, 22, 28, 29, 39, 56–59]
Agent Setting Cut-off for
PD-L1?a
ORR in pts with
PD-L1? tumors,
% (n/N)













Pembrolizumab Advanced melanoma C1 %b 51 (ND) 6 (ND) 12 months 3 months [56]
Pembrolizumab Advanced NSCLC C50 %b 37 (15/41) 11 (10/88) 14.0 weeks 9.3 weeks [57]
Nivolumab Previously-treated
melanoma
C5 %b 44 (8/18) 13 (3/23) 9 months 2 months [22]
Nivolumab Previously-treated
NSCLC
C5 %b 15 (5/33) 14 (5/35) 3.6 months 1.8 months [28]
Nivolumab CTX-naı¨ve NSCLC C5 %b 50 (5/10) 0 (0/7) 45.6 weeks 36.1 weeks [29]






83 (5/6) 20 (4/20) ND ND [39, 59]
MPDL3280A RCC Positive
stainingc
20 (2/10) 10 (2/21) ND ND [11, 59]
MPDL3280A Urothelial bladder
cancer
C5 %d 43 (ND) 11 (ND) ND ND [12]
MEDI4736 NSCLC Undefined 39 (5/13) 5 (1/19) ND ND [14]
MEDI4736 Head and neck
cancer
Undefined 50 (2/4) 6 (1/16) ND ND [14]
CTX chemotherapy, ND no data, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, PD-L1 programmed death ligand 1, pts patients
a Amount of staining required to qualify as a PD-L1? tumor
b Membrane staining of tumor cells
c Staining of tumor-infiltrating immune cells; amount of staining to qualify as a PD-L1? tumor was not defined
d Staining of tumor-infiltrating immune cells
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molecules CTLA-4 and PD-1 [3, 60]. While LAG-3 is
another immune checkpoint that may be important in the
immune response to cancer, blockade of this pathway has
not been clinically evaluated to the same extent as the
CTLA-4 and PD-1 pathways [3]. However, based on the
success of other checkpoint molecules as targets for anti-
cancer therapy, research is now ongoing to assess the
possible clinical value of LAG-3 blockade. IMP321 is a
soluble LAG-3 Ig fusion protein and MHC class II agonist
(Table 1 [4–16]); it has been combined with gemcitabine in
a phase I study in patients with advanced pancreatic ade-
nocarcinoma [15]. IMP321 plus gemcitabine appears to be
a well tolerated regimen that has not resulted in any serious
AEs in patients to date; however, limited antitumor
responses were attributed to the low doses of IMP321. A
small study combining IMP321 and melanoma-associated
antigen immunization in patients with melanoma is ongo-
ing (NCT01308294).
A variety of other molecules that similarly regulate
T-cell activation, tolerance/exhaustion, anergy, and even
T-cell death are currently being assessed as potential tar-
gets for anticancer therapy. One of these inhibitory mole-
cules is T-cell immunoglobulin and mucin domain 3
(TIM3), which is a member of the TIM family (Fig. 1).
TIM3 is expressed by IFN-c-secreting helper T (TH1) cells,
as well as dendritic cells, monocytes, and T cells [61].
When bound to its ligand, galectin-9, TIM3 induces TH1
cell death [62]. Studies of TIM3-deficient mice suggest that
the TIM3 pathway inhibits the expansion and effector
functions of TH1 cells and may be important for tolerance
induction of TH1 cells [63]. Administration of a TIM3
fusion protein resulted in hyperproliferation of TH1 cells
and inflammatory cytokine release, suggesting a ligand for
TIM3 is also expressed by these cells.
Glucocorticoid-induced TNF receptor-related gene
(GITR) can provide a co-stimulatory signal to both CD4?-
and CD8?-naı¨ve T-cells, particularly when T-cell receptor
stimulation is weak [64] (Fig. 1). T cells that do not
express GITR are more prone to activation-induced cell
death, suggesting that GITR-mediated stimulation may
enhance the survival of activated T cells. Also, preclinical
studies showed that agonist anti-GITR antibodies could
reverse regulatory T-cell suppression of effector T cells.
Data from murine models suggest that GITR blockade may
be most effective when combined with melanoma vacci-
nation strategies and not as monotherapy [65]. Currently, a
phase I dose-escalation trial of an anti-GITR monoclonal
antibody (TRX518) is recruiting patients with unresectable
stage III or IV melanoma or other solid tumor malignancies
(NCT01239134).
6 Combination Strategies
Despite promising results as monotherapies, there remains
a clear need to increase the number of patients with
malignancies that can benefit from immune checkpoint
inhibitors. The increasing arsenal of targeted and immune-




C5 9 5 mm)
Always represent PD Incorporated into tumor burden
New, non-
measurable lesions
(i.e., \5 9 5 mm)
Always represent PD Do not define progression (but preclude irCR)
Non-index lesions Changes contribute to defining BOR of CR, PR, SD, and PD Contribute to defining irCR (complete disappearance
required)
CR Disappearance of all lesions in two consecutive observations
not less than 4 weeks apart
Disappearance of all lesions in two consecutive
observations not less than 4 weeks apart
PR C50 % decrease in SPD of all index lesions vs. baseline in
two observations at least 4 weeks apart, in absence of new
lesions or unequivocal progression of non-index lesions
C50 % decrease in tumor burden vs. baseline in two
observations at least 4 weeks apart
SD 50 % decrease in SPD vs. baseline cannot be established nor
25 % increase vs. nadir, in absence of new lesions or
unequivocal progression of non-index lesions
50 % decrease in tumor burden vs. baseline cannot be
established nor 25 % increase vs. nadir
PD At least 25 % increase in SPD vs. nadir and/or unequivocal
progression of non-index lesions and/or appearance of new
lesions (at any single time point)
At least 25 % increase in tumor burden vs. nadir (at any
single time point) in two consecutive observations at
least 4 weeks apart
Reproduced with permission from Wolchok et al. [46]
BOR best overall response, CR complete response, irCR immune-related complete response, PD progressive disease, PR partial response, SD
stable disease, SPD sum of the products of the two largest perpendicular diameters, WHO World Health Organization
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based therapies affords opportunities for sequencing and
combination strategies to improve outcomes. Indeed, rapid
and deep tumor regression was observed in a substantial
number of patients when the CTLA-4 inhibitor, ipi-
limumab, was administered concurrently with nivolumab
[24]. In this study, 42 % of patients had C80 % tumor
reduction at 36 weeks, and 1- and 2-year survival rates
were 85 and 79 %, respectively. Though the efficacy
appeared to be increased as compared with either drug
alone, so did the rate of AEs. The observed toxicities were
similar to those reported with monotherapy, albeit with
higher incidence, including 62 % of patients experiencing
grade 3/4 AEs. Other anti-CTLA-4 plus anti-PD-1 trials are
ongoing, as are trials exploring dual blockade of the PD-1
pathway (anti-PD-1 plus anti-PD-L1) [16]. Additional tri-
als that are planned or have already entered the clinic
include combinations of PD-1 pathway inhibitors with
LAG-3, indolamine 2,3-dioxygenase 1 (IDO1), sipuleucel-
T, or other vaccinations. Immune checkpoint inhibitor
combinations with T-cell agonists (i.e., anti-CD40, anti-
CD27, and anti-4-1BB) and with other immunostimulants
(i.e., IFN, IL-21, and anti-killer immunoglobulin-like
receptor [KIR]) are also underway.
It has been postulated that targeted agents and/or cyto-
toxic chemotherapy that effectively destroy tumor cells
may increase circulating tumor antigens and, therefore,
increase the immunogenic response and utility of check-
point inhibitors [35]. In fact, inhibition of mitogen-acti-
vated protein kinase with BRAF and/or MEK inhibitors in
melanoma cells has been shown to modulate the functions
of immune cells in preclinical studies [66]. While a phase
I/II study (NCT01400451) evaluating the safety and effi-
cacy of combining vemurafenib with ipilimumab recently
closed due to hepatic toxicity, a phase II study of vemu-
rafenib followed by sequential ipilimumab in patients with
V600 BRAF-mutated melanoma is still ongoing. Initial
reports from phase I trials combining nivolumab with
vascular endothelial growth factor (VEGF)-targeted thera-
pies (sunitinib or pazopanib) are currently under study to
determine the best dose and schedule [67, 68]. A combi-
nation regimen of pidilizumab (3 mg/kg) plus rituximab
(375 mg/m2) has also been investigated in a phase II trial in
patients with relapsed follicular lymphoma. Of 29 patients
evaluable for efficacy, 19 had an objective response
(66 %), 15 had a complete response (52 %), and four had a
partial response (14 %) [69].
Trials using ipilimumab combined with various cyto-
toxic chemotherapies, such as temozolomide plus doxy-
cycline (NCT01590082) or fotemustine (NCT01654692)
are underway in patients with metastatic melanoma, as are
numerous trials of PD-1 pathway inhibitors plus chemo-
therapy or targeted agents [16]. Trials evaluating ipi-
limumab plus paclitaxel/carboplatin (NCT01165216) and
pembrolizumab or nivolumab plus chemotherapy or tar-
geted agents (NCT02039674; NCT01454102) have been
started in patients with NSCLC. Details on ongoing phase
II and III trials investigating combination regimens with
immune checkpoint inhibitors are provided in Table 3 [16].
7 Conclusion
A better understanding of tumor immunology and immu-
notherapy, both at the bench and at the bedside, has led to a
new and promising area of basic and clinical cancer
research. Inhibitors of immune checkpoint regulators have
in some cases led to deep and durable responses in patients
with advanced malignancies. Many of the observed side
effects are manageable and reversible following standard
protocols.
Lessons learned from CTLA-4 and PD-1 blockade, in
both the laboratory and the clinic, not only provide the
foundation for a future era of superior immune checkpoint
inhibition, but also provide a nidus of questions that remain
unanswered. Furthering Virchow’s initial observation and
our understanding of the link between the immune system
and malignancy, immune checkpoint inhibitors appear to
offer new hope for cancer patients.
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